Beta Bionics (BBNX) CEO Sean Saint awarded 287,944 stock options at $12.63

Rhea-AI Filing Summary

Beta Bionics, Inc. reported that President & CEO Sean Saint received a grant of employee stock options on Common Stock. The award covers 287,944 options with an exercise price of $12.63 per share and an expiration date of February 26, 2036.

The options were granted at no cost and are classified as a compensation-related acquisition rather than an open-market purchase. According to the vesting terms, the underlying shares will vest in 36 equal monthly installments starting on March 1, 2026, aligning the CEO’s incentives with longer-term company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Saint Sean

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	287,944	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 287,944 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saint Sean

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		287,944		(1)	02/26/2036	Common Stock	287,944	$0	287,944	D

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Remarks:

The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics (BBNX) CEO Sean Saint receive in this Form 4/A?

Sean Saint received a grant of 287,944 employee stock options on Beta Bionics common stock. These options are a compensation award, not an open-market share purchase, and give him the right to buy shares at a fixed exercise price if they vest and are exercised.

What is the exercise price and term of the new BBNX stock options?

The granted options have an exercise price of $12.63 per share and expire on February 26, 2036. This means Sean Saint can choose to buy Beta Bionics common shares at $12.63 up until that expiration date, subject to vesting conditions being met.

How do the CEO’s new Beta Bionics options vest over time?

The options vest in 36 equal monthly installments starting from March 1, 2026. Each month, a portion of the 287,944 underlying shares becomes exercisable, creating a multi-year incentive structure tied to Sean Saint’s continued service and company performance.

Is the BBNX CEO’s Form 4/A transaction a stock purchase or sale?

The filing shows a grant/award acquisition of stock options, not a purchase or sale of common shares in the market. It reflects equity-based compensation, with no reported open-market buying or selling activity by Sean Saint in this particular Form 4/A.

How many Beta Bionics options does the CEO hold after this grant?

After this transaction, Sean Saint holds 287,944 employee stock options related to Beta Bionics common stock from this grant. These options become exercisable gradually under the 36‑month vesting schedule and can be used to acquire shares at the fixed exercise price if exercised.